Skip to main content

BG Medicine Files for IPO on Euronext Amsterdam Exchange

NEW YORK (GenomeWeb News) - BG Medicine today said it has filed for an initial public offering of its shares on the Euronext Amsterdam Exchange.
 
The biomarker and diagnostics developer said it has filed a registration statement with the US Securities and Exchange Commission but has not yet determined the number of shares it plans to issue and it has not set an opening price for its common stock.
 
BG Medicine said it plans to trade on the Euronext Amsterdam market by the New York Stock Exchange's Euronext under the symbol BGMDX.
 
Cowen International and Fortis will serve as global coordinators and book-runners and Leerink Swann & Co. will co-manage the offering.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.